Hengsai Biotechnology
PrivateLast Round
Strategic
Dec 30, 2025
Total Funding Raised
$22.87M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Hengsai Biotechnology operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Strategic round in December 2025.
Hengsai Biotechnology is a biotechnology company that develops therapeutic dendritic cell (DC) vaccines for the treatment of tumors, chronic viral infections, and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Hengsai Biotechnology Comparables
Compare Hengsai Biotechnology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| CoImmune, Inc. | 82% | |
| Elios Therapeutics | 80% | |
| Diakonos Oncology | 78% |
For institutional investors. Book with your work email.
Hengsai Biotechnology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Strategic | Dec 30, 2025 | ||||
| Series A Extension | Jan 17, 2024 | ||||
| Series A | Nov 27, 2023 | ||||
| Pre Seed | Apr 20, 2022 |
For institutional investors. Book with your work email.
Hengsai Biotechnology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| 中山创业投资有限公司 | Series A Extension |
| Fuhui Venture Capital | Series A, Pre Seed |
| Beijing Chengming Private Equity Fund Management Co., Ltd. | Series A Extension |
| Zhongshan Cuiheng Group Co., Ltd. | Series A Extension |
| Tasly Capital | Strategic |
| Zhongshan Venture Capital Co., Ltd. | Series A Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 30, 2025
Led by Tasly Capital
- Jan 17, 2024
$4M raised from Beijing Chengming and Zhongshan Venture Capital.
For institutional investors. Book with your work email.
Hengsai Biotechnology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Hengsai Biotechnology's valuation, stock price, and market status.
Is Hengsai Biotechnology a public or private company?
Hengsai Biotechnology is a private company.
What is the current stock price of Hengsai Biotechnology?
Hengsai Biotechnology is a private company, so its shares have no public market price. Caplight tracks Hengsai Biotechnology's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Hengsai Biotechnology worth (valuation)?
Valuation information for Hengsai Biotechnology is not publicly available.
Can I buy Hengsai Biotechnology stock?
Hengsai Biotechnology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Hengsai Biotechnology's last funding round?
Hengsai Biotechnology's most recent funding round was Strategic on December 30, 2025.
Who are the main investors in Hengsai Biotechnology?
Key investors in Hengsai Biotechnology include Fuhui Venture Capital, Tasly Capital.
Will Hengsai Biotechnology IPO soon?
No public IPO plans have been announced for Hengsai Biotechnology.
How can I track Hengsai Biotechnology secondary market activity?
Caplight tracks bids, offers, and trades in Hengsai Biotechnology's shares on secondary markets.